首页分子通化学资讯化学百科反应查询关于我们

请输入关键词

历史搜索

热门化合物HOT

喹啉
水杨醛
二溴甲烷
谷胱甘肽
L-乳酸
苯巴比妥
辣椒碱
非那明
百草枯
联苯烯

2',3'-isopropylideneadenosine-5'-carboxylic acid | 19234-66-3

分子结构分类

有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷

中文名称

——

中文别名

——

英文名称

2',3'-isopropylideneadenosine-5'-carboxylic acid

英文别名

2',3'-O-isopropylideneadenosine-5'-carboxylic acid；(3aS,4S,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carboxylic acid；2',3'-O-isopropylideneadenosine-5'-uronic acid；2',3'-Isopropyliden-adenosin-5'-carbonsaeure；(3aR,4R,6S,6aS)-4-(6-aminopurin-9-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carboxylic acid

2',3'-isopropylideneadenosine-5'-carboxylic acid化学式

CAS

19234-66-3

化学式

C₁₃H₁₅N₅O₅

mdl

——

分子量

321.293

InChiKey

RRTBBKSJPNRFCG-MCHASIABSA-N

BEILSTEIN

——

EINECS

——

物化性质

熔点：

276-279°C
沸点：

628.9±65.0 °C(Predicted)
密度：

1.92±0.1 g/cm3(Predicted)
溶解度：

可溶于DMSO（轻微）、甲醇（轻微、加热）

计算性质

辛醇/水分配系数(LogP)：

-0.6
重原子数：

23
可旋转键数：

2
环数：

4.0
sp3杂化的碳原子比例：

0.54
拓扑面积：

135
氢给体数：

2
氢受体数：

9

SDS

SDS：79916f32c7a69b2e78a9780eca8d86d5

查看

上下游信息

上游原料

中文名称	英文名称	CAS号	化学式	分子量
2',3'-异丙叉腺苷	2',3'-isopropylidene adenosine	362-75-4	C₁₃H₁₇N₅O₄	307.309
——	(3aS,4S,6R,6aR)-6-(6-Amino-purin-9-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carboxylic acid 4-nitro-phenyl ester	159647-45-7	C₁₉H₁₈N₆O₇	442.388
腺苷	adenosine	58-61-7	C₁₀H₁₃N₅O₄	267.244
——	5'-(O-tert-butyldimethylsilyl)adenosine	69530-93-4	C₁₆H₂₇N₅O₄Si	381.507

下游产品

中文名称	英文名称	CAS号	化学式	分子量
——	2',3'-O-isopropylideneadenosine-5'-carboxylic acid methyl ester	23754-29-2	C₁₄H₁₇N₅O₅	335.319
——	1-(6-amino-purin-9-yl)-O²,O³-isopropylidene-β-D-1-deoxy-ribofuranuronic acid ethyl ester	35803-48-6	C₁₅H₁₉N₅O₅	349.346
——	(3aS,4S,6R,6aR)-6-(6-Amino-purin-9-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carboxylic acid 4-nitro-phenyl ester	159647-45-7	C₁₉H₁₈N₆O₇	442.388
——	5'-N-methyl-2',3'-O-isopropylidenecarboxamidoadenosine	39491-51-5	C₁₄H₁₈N₆O₄	334.335
——	(3aR,4R,6S,6aS)-4-(6-aminopurin-9-yl)-N-hydroxy-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carboxamide	1034341-32-6	C₁₃H₁₆N₆O₅	336.307
——	ethyl (3aR,4R,6S,6aS)-4-(6-chloropurin-9-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carboxylate	176166-66-8	C₁₅H₁₇ClN₄O₅	368.777
5'-乙基甲酰氨基-2',3'-异亚丙基腺苷	adenosine-5'-N-ethyluronamide	39491-53-7	C₁₅H₂₀N₆O₄	348.362
——	5'-N-(n-propyl)-2',3'-O-isopropylidenecarboxamidoadenosine	222527-40-4	C₁₆H₂₂N₆O₄	362.388
——	(3aR,4R,6S,6aS)-4-(6-aminopurin-9-yl)-N-butyl-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carboxamide	159625-87-3	C₁₇H₂₄N₆O₄	376.415
——	(3aR,4R,6S,6aS)-4-(6-aminopurin-9-yl)-2,2-dimethyl-N-pentyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carboxamide	1053699-95-8	C₁₈H₂₆N₆O₄	390.442
——	(3aR,4R,6S,6aS)-N-(8-aminooctyl)-4-(6-aminopurin-9-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carboxamide	1054746-65-4	C₂₁H₃₃N₇O₄	447.538
——	(3aR,4R,6S,6aS)-4-(6-aminopurin-9-yl)-2,2-dimethyl-N-undecyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carboxamide	1053255-99-4	C₂₄H₃₈N₆O₄	474.604
——	(3aR,4R,6S,6aS)-N-(8-acetamidooctyl)-4-(6-aminopurin-9-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carboxamide	1053626-23-5	C₂₃H₃₅N₇O₅	489.575
——	(3aR,4R,6S,6aS)-N-(2-aminoethyl)-4-(6-aminopurin-9-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carboxamide	152918-45-1	C₁₅H₂₁N₇O₄	363.376
——	5'-N-(2-chloroethyl)-2',3'-O-isopropylidenecarboxamidoadenosine	——	C₁₅H₁₉ClN₆O₄	382.807
——	5'-N-isopropyl-2',3'-O-isopropylidenecarboxamidoadenosine	222527-41-5	C₁₆H₂₂N₆O₄	362.388
——	5'-N-(2-fluoroethyl)-2',3'-O-isopropylidene-carboxamidoadenosine	——	C₁₅H₁₉FN₆O₄	366.352
——	5'-N-(2-[18F]fluoroethyl)-2',3'-O-isopropylidene-carboxamidoadenosine	291771-78-3	C₁₅H₁₉FN₆O₄	365.354
——	ethyl (3aR,4R,6S,6aS)-4-[6-(2,2-diphenylethylamino)purin-9-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carboxylate	176166-67-9	C₂₉H₃₁N₅O₅	529.596
2',3'-O-异亚丙基肌苷-5'-甲酸	2',3'-O-isopropylideneinosine-5'-carboxylic acid	28440-13-3	C₁₃H₁₄N₄O₆	322.277
——	5'-N-(2,2,2-trifluoroethyl)-[(2,3-O-isopropylidene-β-D-ribofuranosyl)adenine]uronamide	——	C₁₅H₁₇F₃N₆O₄	402.333
——	5'-N-(tert-butyl)-2',3'-O-isopropylidenecarboxamidoadenosine	222527-43-7	C₁₇H₂₄N₆O₄	376.415
——	2',3'-O-isopropylideneadenosine-5'-(N-methoxy)carboxamide	54925-48-3	C₁₄H₁₈N₆O₅	350.334
——	(3aS,4S,6R,6aR)-6-(6-Amino-purin-9-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carboxylic acid sec-butylamide	1053644-59-9	C₁₇H₂₄N₆O₄	376.415
——	5'-N-cyclopropyl-2',3'-O-isopropylidenecarboxamidoadenosine	58048-28-5	C₁₆H₂₀N₆O₄	360.373
——	5'-N,N-ethylene-2',3'-O-isopropylidenecarboxamidoadenosine	——	C₁₅H₁₈N₆O₄	346.346
——	1-(6-amino-purin-9-yl)-O²,O³-isopropylidene-β-D-1-deoxy-ribofuranuronic acid ethoxyamide	54925-49-4	C₁₅H₂₀N₆O₅	364.361
——	ethyl adenosine-5'-carboxylate	35803-57-7	C₁₂H₁₅N₅O₅	309.282
——	(3aS,4S,6R,6aR)-6-(6-Amino-purin-9-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carboxylic acid diethylamide	——	C₁₇H₂₄N₆O₄	376.415
腺苷酸-5-羧酸	adenosine 5'-carboxylic acid	3415-09-6	C₁₀H₁₁N₅O₅	281.228
——	(2R)-2-[[(3aR,4R,6S,6aS)-4-(6-aminopurin-9-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carbonyl]amino]propanoic acid	1374251-01-0	C₁₆H₂₀N₆O₆	392.371
——	(3aR,4R,6S,6aS)-N-(2-adamantyl)-4-(6-aminopurin-9-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carboxamide	1054667-98-9	C₂₃H₃₀N₆O₄	454.529
——	5'-N-ethyl-2',3'-O-isopropylidenethiocarboxamidoadenosine	222527-48-2	C₁₅H₂₀N₆O₃S	364.428
——	(3aR,4R,6S,6aS)-4-[6-(2,2-diphenylethylamino)purin-9-yl]-N-ethyl-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carboxamide	176166-72-6	C₂₉H₃₂N₆O₄	528.611
——	N-{2,2-dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-d][1,3]dioxole-4-carbonyl}-methanesulfonamide	——	C₂₁H₂₃N₇O₇S	517.522
——	(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(1-hydroxyethyl)tetrahydrofuran-3,4-diol	847659-02-3	C₁₁H₁₅N₅O₄	281.271
——	(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((S)-1-hydroxyethyl)tetrahydrofuran-3,4-diol	35868-16-7	C₁₁H₁₅N₅O₄	281.271
——	(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((R)-1-hydroxyethyl)tetrahydrofuran-3,4-diol	3253-81-4	C₁₁H₁₅N₅O₄	281.271
5-(6-氨基嘌呤-9-基)-3,4-二羟基四氢呋喃-2-甲酰胺	adenosine 5'-carboxamide	35788-21-7	C₁₀H₁₂N₆O₄	280.243
5'-N-甲基甲酰氨基腺苷	5'-N-methylcarboxamidoadenosine	35788-27-3	C₁₁H₁₄N₆O₄	294.27
——	1-(6-amino-purin-9-yl)-β-D-1-deoxy-ribofuranuronic acid hydroxyamide	35788-24-0	C₁₀H₁₂N₆O₅	296.242
——	1-(6-amino-purin-9-yl)-β-D-1-deoxy-ribofuranuronic acid prop-2-ynylamide	51094-98-5	C₁₃H₁₄N₆O₄	318.292
5-N-乙基酰胺基腺苷	5'-N-Ethylcarboxamidoadenosine	35920-39-9	C₁₂H₁₆N₆O₄	308.297
——	(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-N-propyltetrahydrofuran-2-carboxamide	57872-80-7	C₁₃H₁₈N₆O₄	322.324
——	(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-(2,2-difluoroethyl)-3,4-dihydroxytetrahydrofuran-2-carboxamide	1374250-80-2	C₁₂H₁₄F₂N₆O₄	344.278
——	1-(6-amino-purin-9-yl)-β-D-1-deoxy-ribofuranuronic acid hexylamide	57872-78-3	C₁₆H₂₄N₆O₄	364.404
——	adenosine-5'-(N-butylcarboxamide)	35788-23-9	C₁₄H₂₀N₆O₄	336.351
——	5'-N-[(2-Amino)ethyl Carboxamido] Adenosine	66822-83-1	C₁₂H₁₇N₇O₄	323.311
——	5'-N-isopropylcarboxamidoadenosine	35788-29-5	C₁₃H₁₈N₆O₄	322.324
——	(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-N-(2,2,2-trifluoroethyl)tetrahydrofuran-2-carboxamide	——	C₁₂H₁₃F₃N₆O₄	362.268
——	(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-(3-fluoropropyl)-3,4-dihydroxytetrahydrofuran-2-carboxamide	1374250-81-3	C₁₃H₁₇FN₆O₄	340.314
——	(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-((2S)-2,3-dihydroxypropyl)-3,4-dihydroxytetrahydrofuran-2-carboxamide	1374250-83-5	C₁₃H₁₈N₆O₆	354.323
——	(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-(2-fluoroethyl)-3,4-dihydroxytetrahydrofuran-2-carboxamide	——	C₁₂H₁₅FN₆O₄	326.287
5-(N-环丙基)酰胺酰酐	5-(N-cyclopropyl)carboxamidoadenosine	50908-62-8	C₁₃H₁₆N₆O₄	320.308
——	adenosine-5'-(N-methoxy)carboxamide	54925-45-0	C₁₁H₁₄N₆O₅	310.269
——	(2S,3S,4R,5R)-N-(6-(1,4,7,10-tetraazacyclododecan-1-yl)-6-oxohexyl)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-carboxamide	——	C₂₄H₄₀N₁₀O₅	548.646
——	(2S,3S,4R,5R)-N-(2-amino-2-oxoethyl)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-carboxamide	1374250-84-6	C₁₂H₁₅N₇O₅	337.295
——	1-(6-amino-purin-9-yl)-β-D-1-deoxy-ribofuranuronic acid ethoxyamide	54925-46-1	C₁₂H₁₆N₆O₅	324.296
——	(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-cyclobutyl-3,4-dihydroxytetrahydrofuran-2-carboxamide	55549-09-2	C₁₄H₁₈N₆O₄	334.335
——	1-(6-amino-purin-9-yl)-β-D-1-deoxy-ribofuranuronic acid cyclohexylamide	35788-32-0	C₁₆H₂₂N₆O₄	362.388
——	adenosine-5'-(N-phenylcarboxamide)	72758-43-1	C₁₆H₁₆N₆O₄	356.341
——	(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-cyclopentyl-3,4-dihydroxytetrahydrofuran-2-carboxamide	35920-40-2	C₁₅H₂₀N₆O₄	348.362
——	(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-(3-fluorocyclobutyl)-3,4-dihydroxytetrahydrofuran-2-carboxamide	1374299-84-9	C₁₄H₁₇FN₆O₄	352.325
——	(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-(D-alanyl)-3,4-dihydroxytetrahydrofuran-2-carboxamide	1374250-86-8	C₁₃H₁₆N₆O₆	352.307
——	(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-N-((R)-tetrahydrofuran-3-yl)tetrahydrofuran-2-carboxamide	1374250-90-4	C₁₄H₁₈N₆O₅	350.334
——	(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-(3,3-difluorocyclobutyl)-3,4-dihydroxytetrahydrofuran-2-carboxamide	1374250-88-0	C₁₄H₁₆F₂N₆O₄	370.316
2',3'-O-异亚丙基-5'-氧-8,5'-CYCLO腺苷	2',3'-O-isopropylidene-5'-oxo-8,5'-cycloadenosine	33066-26-1	C₁₃H₁₃N₅O₄	303.277
——	(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-(2,2-difluorocyclopropyl)-3,4-dihydroxytetrahydrofuran-2-carboxamide	1374250-87-9	C₁₃H₁₄F₂N₆O₄	356.289
——	beta-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-1-deoxy-N-tricyclo(3.3.1.1(sup 3,7)dec-1-yl)-	58048-16-1	C₂₀H₂₆N₆O₄	414.464
——	(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-N-(4H-1,2,4-triazol-3-yl)tetrahydrofuran-2-carboxamide	1374250-92-6	C₁₂H₁₃N₉O₄	347.293
——	(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-N-(1H-pyrazol-3-yl)tetrahydrofuran-2-carboxamide	1374250-91-5	C₁₃H₁₄N₈O₄	346.305
——	(2S)-2-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]amino]-4-phenylbutanoic acid	1414794-95-8	C₂₀H₂₂N₆O₆	442.431
——	(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-N-[(2S)-1-[4-[2-(dipropylamino)ethyl]piperazin-1-yl]-1-oxo-4-phenylbutan-2-yl]-3,4-dihydroxyoxolane-2-carboxamide	1414799-31-7	C₃₂H₄₇N₉O₅	637.782
——	(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-N-[(2S)-1-oxo-1-[4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazin-1-yl]-4-phenylbutan-2-yl]oxolane-2-carboxamide	1414799-40-8	C₃₀H₃₉N₉O₆	621.696
——	(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-N-[(2S)-1-[bis(2-methoxyethyl)amino]-1-oxo-4-phenylbutan-2-yl]-3,4-dihydroxyoxolane-2-carboxamide	1414795-16-6	C₂₆H₃₅N₇O₇	557.607
——	(2S)-1-[(2S)-2-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]amino]-4-phenylbutanoyl]pyrrolidine-2-carboxamide	1414798-93-8	C₂₅H₃₀N₈O₆	538.563
——	(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-N-[(2S)-1-oxo-4-phenyl-1-[4-(2,2,2-trifluoroacetyl)piperazin-1-yl]butan-2-yl]oxolane-2-carboxamide	1414799-05-5	C₂₆H₂₉F₃N₈O₆	606.561
——	(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-N-[(2S)-1-[(2-morpholin-4-yl-2-oxoethyl)amino]-1-oxo-4-phenylbutan-2-yl]oxolane-2-carboxamide	1414798-97-2	C₂₆H₃₂N₈O₇	568.589
——	N⁶-(2,2-diphenylethyl)-5'-N-ethylcarboxamidoadenosine	——	C₂₆H₂₈N₆O₄	488.546
——	4-[(2S)-2-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]amino]-4-phenylbutanoyl]-N,N-dimethylpiperazine-1-carboxamide	1414799-12-4	C₂₇H₃₅N₉O₆	581.632
——	(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-N-[(2S)-1-[piperdine-4-carbonylpiperazin-1-yl]-1-oxo-4-phenylbutan-2-yl]oxolane-2-carboxamide	1414799-17-9	C₃₀H₃₉N₉O₆	621.696
——	(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-N-[(2S)-1-[4-(morpholine-4-carbonyl)piperazin-1-yl]-1-oxo-4-phenylbutan-2-yl]oxolane-2-carboxamide	1414799-23-7	C₂₉H₃₇N₉O₇	623.669
——	(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-N-[(2S)-1-oxo-4-phenyl-1-[4-(thiophen-2-ylmethyl)-1,4-diazepan-1-yl]butan-2-yl]oxolane-2-carboxamide	1414795-31-5	C₃₀H₃₆N₈O₅S	620.732
——	(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-N-[(2S)-1-[[2-(2,3-dimethylanilino)-2-oxoethyl]-amino]-1-oxo-4-phenylbutan-2-yl]-3,4-dihydroxyoxolane-2-carboxamide	1414798-85-8	C₃₀H₃₄N₈O₆	602.65
——	(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-N-[(2S)-1-[4-(2-methoxybenzoyl)piperazin-1-yl]-1-oxo-4-phenylbutan-2-yl]oxolane-2-carboxamide	1414798-83-6	C₃₂H₃₆N₈O₇	644.687

反应信息

作为反应物：

描述：

2',3'-isopropylideneadenosine-5'-carboxylic acid 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、三乙胺、 N,N-二异丙基乙胺作用下，以 N,N-二甲基甲酰胺为溶剂，反应 8.0h，生成 (2S,3S,4R,5R)-N-(3-(6-amino-9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-8-yl)prop-2-yn-1-yl)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-carboxamide

参考文献：

名称：

[EN] NOVEL ANTIBACTERIAL COMPOUNDS
[FR] NOUVEAUX COMPOSÉS ANTIBACTÉRIENS

摘要：

本发明涉及以下化合物的公式(I)：其中R1、R2、R3、R4、X1、X2、X3和Z的定义如权利要求1所述。这些化合物在预防和/或治疗细菌感染方面具有用途。

公开号：

WO2012090136A1
作为产物：

描述：

2',3'-异丙叉腺苷在 2,2,6,6-四甲基哌啶氧化物、碘苯二乙酸作用下，以水、乙腈为溶剂，以90%的产率得到2',3'-isopropylideneadenosine-5'-carboxylic acid

参考文献：

名称：

Rv3406通过策略性核苷修饰避免结核分枝杆菌的抗生素失活

摘要：

5'-[ N-（d-生物氨酰基）氨磺酰基]氨基-5'-脱氧腺苷（Bio-AMS，1）具有抗结核分枝杆菌（Mtb）的选择性活性，并通过抑制结核分枝杆菌生物素蛋白而阻止脂肪酸和脂质的生物合成。连接酶（Mt BPL）。Mtb通过过表达Rv3406（一种酶使1失活的II型硫酸酯酶），以至少1×10 –7的频率对1产生自发抗性。。为了避免这种抗性机制，我们在本文中描述了在5'-位置对核苷进行策略性修饰以防止酶促失活。新类似物保留亚纳摩尔效力山BPL（ķ d = 0.66-0.97纳米），和5' - [R - c ^ -甲基衍生物6显示出相同的抗分支杆菌活性的朝向：Mtb的分枝杆菌H37Rv，山BPL过表达，和同基因Rv3406过表达菌株（最小抑制浓度，MIC = 1.56μM）。此外，重组Rv3406不能代谢6个，并且不能分离出对6个有抗性的突变体（抗性频率<1.4×10–10）证明它成功克服了Rv3406介导的抗性。

DOI：

10.1021/acsinfecdis.8b00038

点击查看最新优质反应信息

文献信息

The discovery and synthesis of novel adenosine substituted 2,3-dihydro-1H-isoindol-1-ones: potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1)

作者：Prakash G. Jagtap、Garry J. Southan、Erkan Baloglu、Siya Ram、Jon G. Mabley、Anita Marton、Andrew Salzman、Csaba Szabó

DOI：10.1016/j.bmcl.2003.10.007

日期：2004.1

A series of novel 4-(N-acyl)-2,3-dihydro-1H-isoindol-1-ones have been prepared from methyl-3-nitro-2-methylbenzoate and linked through various spacers to the adenosine derivatives 11 and 12. We found that potent inhibition of poly(ADP-ribose)polymerase-1 (PARP-1) was achieved when isoindolinone was linked to adenosine by a spacer group of a specific length. Introduction of piperazine and succinyl linkers

由3-硝基-2-甲基苯甲酸甲酯制备了一系列新颖的4-（N-酰基）-2,3-二氢-1H-异吲哚-1-酮，并通过各种间隔基连接到腺苷衍生物11和12上。我们发现，当异吲哚啉酮通过特定长度的间隔基团连接到腺苷时，可以有效抑制聚（ADP-核糖）聚合酶-1（PARP-1）。在异吲哚啉酮和腺苷核心结构之间引入哌嗪和琥珀酰连接基可产生强效化合物8a和10b，其IC（50）值分别为45和100 nM。
SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS

申请人：Pfizer Inc.

公开号：US20160244475A1

公开（公告）日：2016-08-25

Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

通式（I）的化合物：制备这些化合物的方法，含有这些化合物的组合物，以及这些化合物的用途。
Solventless Protocol for Efficient Bis-<i>N</i>-Boc Protection of Adenosine, Cytidine, and Guanosine Derivatives

作者：Siddharth A. Sikchi、Philip G. Hultin

DOI：10.1021/jo060430t

日期：2006.8.1

A solvent-free reaction employing a simple low-energy ball mill apparatus converts the amino groups of adenosine, 2-deoxyadenosine, cytidine, 2-deoxycytidine, guanosine, and 2-deoxyguanosine as well as some of their ribosyl O-protected derivatives to the corresponding bis-N-Boc carbamates. In the case of guanosine compounds, the carbonyl group of the base moiety was also blocked as its O-Boc enol carbonate

使用简单的低能球磨仪进行的无溶剂反应将腺苷，2-脱氧腺苷，胞嘧啶核苷，2-脱氧胞苷，鸟苷和2-脱氧鸟苷的氨基以及它们的一些核糖基O保护的衍生物转化为相应的bis- N -Boc氨基甲酸酯。在鸟苷化合物的情况下，该碱基部分的羰基也被封闭为其O- Boc烯醇碳酸酯。使用瞬态原位O硅烷化的这种方法的一种变体允许制备bis- N-Boc核苷，其中糖羟基不受保护。除鸟苷化合物外，球磨反应迅速，方便且产率很高。这种高效的方法使用适合进一步合成操作的碱稳定且酸不稳定的基团保护这些核苷的氨基。
[EN] NON-NUCLEOTIDE COMPOSITIONS AND METHOD FOR TREATING PAIN<br/>[FR] COMPOSITIONS NON-NUCLEOTIDIQUES ET PROCEDE DE TRAITEMENT DE LA DOULEUR

申请人：INSPIRE PHARMACEUTICALS INC

公开号：WO2005039590A1

公开（公告）日：2005-05-06

The present invention is directed to a method of treating pain. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a P2X receptor antagonist. The methods of the present invention are useful in reducing pain, such as traumatic pain, neuropathic pain, organ pain and/or pain associated with diseases. The P2X receptor antagonists useful for this invention are non-nucleotide compounds of general Formula I. Compounds of Formula I can be used alone to treat pain. Compounds of Formula I can also be used in conjunction with other therapeutic agents or adjunctive therapies commonly used to treat pain, thus enhancing the therapeutic effect of pain reduction.

本发明涉及一种治疗疼痛的方法。该方法包括向受试者施用含有有效量P2X受体拮抗剂的药物组合物。本发明的方法对于减轻疼痛，如创伤性疼痛、神经病性疼痛、器官疼痛和/或与疾病相关的疼痛具有用处。本发明中用于该发明的P2X受体拮抗剂是一般式I的非核苷化合物。式I的化合物可以单独用于治疗疼痛。式I的化合物也可以与其他治疗剂或常用于治疗疼痛的辅助疗法结合使用，从而增强减轻疼痛的治疗效果。
[EN] TETRAHYDRO-FURO`3,4-D!DIOXOLE COMPOUNDS AND COMPOSITIONS AND METHOD FOR INHIBITING PLATELET AGGREGATION<br/>[FR] COMPOSES TETRAHYDRO-FURO[3,4D]DIOXOLE, ET COMPOSITIONS ET PROCEDE POUR INHIBER UNE AGREGATION PLAQUETTAIRE

申请人：INSPIRE PHARMACEUTICALS INC

公开号：WO2005040174A1

公开（公告）日：2005-05-06

This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae I and III-XI, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds according to Formulae I and III-XI.

这项发明涉及一种预防或治疗与血小板聚集相关的疾病或症状的方法。该方法还涉及一种治疗血栓形成或相关疾病的方法。该方法包括向受试者施用含有有效量非核苷酸化合物的药物组合物，优选为P2Y12受体拮抗剂化合物，其中所述量有效地抑制血小板聚集。本发明有用的化合物包括一般式I和III-XI的化合物，或其盐、水合物和溶剂合物。本发明还提供了根据一般式I和III-XI的新化合物。